Suppr超能文献

影响肺毛霉病患者手术切除及治疗结果的因素。

Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis.

作者信息

Choi Hayoung, Lee Hyun, Jeon Kyeongman, Suh Gee Young, Shin Sumin, Kim Hong Kwan, Kim Kyunga, Jeong Daecheon, Kim Hojoong

机构信息

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea.

Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

出版信息

J Thorac Dis. 2019 Mar;11(3):892-900. doi: 10.21037/jtd.2019.01.75.

Abstract

BACKGROUND

Surgical resection is the cornerstone treatment for pulmonary mucormycosis, a lethal fungal infection. It is unclear why some patients do not receive surgery, and the natural courses of these patients have not been well evaluated.

METHODS

A retrospective review was performed using the medical records of 20 patients with pathologically-confirmed pulmonary mucormycosis. We evaluated the reasons for not receiving surgery and compared treatment outcomes between patients who did and did not undergo surgery.

RESULTS

Overall survival rate was 50%. Nine of 11 (82%) patients who underwent surgery survived; however, only 1 of 9 (11%) patients who did not undergo surgery survived. Reasons for not receiving surgery were death shortly after diagnosis (n=1), altered mental state (n=1), refractory underlying disease (n=3), and refusal by patient due to concern of operative risk (n=4). Patients who did not undergo surgery were more likely to be older (P=0.018), have a longer duration of steroid use (P=0.021), higher lactate dehydrogenase level (P=0.039), higher sequential organ failure assessment (SOFA) score (P=0.035), and higher rate of cytomegalovirus (CMV) infection (P=0.020) than those did receive surgery. Surgery was the only favorable survival factor in multivariable analyses (adjusted odds ratio for survival =15.45; P=0.029).

CONCLUSIONS

The main reasons for not undergoing surgery in patients with pulmonary mucormycosis were the gravity of underlying diseases and concerns for operative risk. Although overall survival rate was poor, it was significantly higher in patients who received pulmonary resection surgery. The decision to undergo lung resection is time-sensitive and essential in improving survival rate in patients suffering from pulmonary mucormycosis, despite perioperative risks.

摘要

背景

手术切除是治疗肺毛霉菌病(一种致命的真菌感染)的基石性治疗方法。目前尚不清楚为何有些患者未接受手术治疗,且这些患者的自然病程也未得到充分评估。

方法

对20例经病理确诊的肺毛霉菌病患者的病历进行回顾性分析。我们评估了未接受手术的原因,并比较了接受手术和未接受手术患者的治疗结果。

结果

总体生存率为50%。11例接受手术的患者中有9例(82%)存活;然而,9例未接受手术的患者中仅有1例(11%)存活。未接受手术的原因包括诊断后不久死亡(n = 1)、精神状态改变(n = 1)、难治性基础疾病(n = 3)以及患者因担心手术风险而拒绝手术(n = 4)。未接受手术的患者比接受手术的患者年龄更大(P = 0.018)、使用类固醇的时间更长(P = 0.021)、乳酸脱氢酶水平更高(P = 0.039)、序贯器官衰竭评估(SOFA)评分更高(P = 0.035)以及巨细胞病毒(CMV)感染率更高(P = 0.020)。在多变量分析中,手术是唯一有利的生存因素(生存调整比值比 = 15.45;P = 0.029)。

结论

肺毛霉菌病患者未接受手术的主要原因是基础疾病严重和担心手术风险。尽管总体生存率较低,但接受肺切除手术的患者生存率显著更高。尽管存在围手术期风险,但对于肺毛霉菌病患者而言,决定是否进行肺切除手术对提高生存率至关重要且具有时间敏感性。

相似文献

7
COVID associated pulmonary mucormycosis: Outcomes of surgical therapy.新型冠状病毒肺炎相关肺毛霉菌病:外科治疗的结果
Asian Cardiovasc Thorac Ann. 2023 Feb;31(2):133-141. doi: 10.1177/02184923221140258. Epub 2022 Nov 24.

引用本文的文献

5
What Is New in Pulmonary Mucormycosis?肺毛霉病有哪些新进展?
J Fungi (Basel). 2023 Feb 28;9(3):307. doi: 10.3390/jof9030307.
8
Pulmonary Mucormycosis Involving the Left Main Bronchus and the Pulmonary Artery.左主支气管和肺动脉受累的肺毛霉菌病。
Ann Thorac Cardiovasc Surg. 2023 Dec 20;29(6):315-318. doi: 10.5761/atcs.cr.22-00035. Epub 2022 Apr 6.
10
Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India.COVID-19 大流行中的毛霉菌病:印度一家三级医院的研究。
Eur Arch Otorhinolaryngol. 2022 Jun;279(6):3201-3210. doi: 10.1007/s00405-022-07282-1. Epub 2022 Feb 5.

本文引用的文献

4
Pulmonary mucormycosis.肺毛霉病。
Semin Respir Crit Care Med. 2011 Dec;32(6):693-702. doi: 10.1055/s-0031-1295717. Epub 2011 Dec 13.
5
How I treat mucormycosis.我如何治疗毛霉病。
Blood. 2011 Aug 4;118(5):1216-24. doi: 10.1182/blood-2011-03-316430. Epub 2011 May 26.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验